Literature DB >> 2888319

Functional significance of alpha-adrenergic receptors in mature coronary collateral circulation of dogs.

Y Maruoka, M D McKirnan, R L Engler, J C Longhurst.   

Abstract

There is little information on the functional significance of alpha-adrenergic receptors in the dog's coronary collateral circulation. Accordingly, we investigated the effects of infusion of either norepinephrine (NE) or B-HT 920 (BHT), an alpha 2-adrenergic agonist, on vascular resistance of coronary collaterals in chloralose-anesthetized dogs 2-3 mo after placement of an Ameroid constrictor around the left circumflex coronary (LCX) artery. To accomplish this, the vagotomized left ventricle was autoperfused through the left main coronary ostium using a servo-controlled constant-pressure pump. Pressures of the left anterior descending (LAD) and peripheral LCX arteries were measured, and regional blood flow in LAD and LCX regions were determined with radioactive microspheres before and during NE infusion in the unblocked condition, following beta-adrenergic and beta + alpha 1-adrenergic blockade with the use of propranolol and prazosin, respectively. The same parameters were also measured before and during BHT infusion following beta-adrenergic and beta + alpha 2-adrenergic blockade with the use of propranolol and idazoxan, respectively. In the unblocked condition, NE reduced LAD, LCX, and collateral resistance by 43, 50, and 31%, respectively. After beta-adrenergic blockade, NE increased LAD resistance (29%) but did not alter LCX or collateral resistance. The increase in LAD resistance was abolished following alpha 1-adrenergic blockade. BHT increased vascular resistance in LAD, LCX, and collateral circulations by 35, 29, and 45%, respectively. Selective alpha 2-adrenergic blockade significantly attenuated the vasoconstrictor response to BHT.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2888319     DOI: 10.1152/ajpheart.1987.253.3.H582

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

1.  Alpha-adrenergic inhibition increases collateral circuit conductance in rats following acute occlusion of the femoral artery.

Authors:  Jessica C Taylor; Zeyi Li; H T Yang; M Harold Laughlin; Ronald L Terjung
Journal:  J Physiol       Date:  2008-01-24       Impact factor: 5.182

2.  Impairment of the myocardial vasomotor response to cold pressor stress in collateral dependent myocardium.

Authors:  N G Uren; T Crake; D Tousoulis; C Seydoux; G J Davies; A Maseri
Journal:  Heart       Date:  1997-07       Impact factor: 5.994

3.  Alpha 1-adrenoceptor activation mediates the infarct size-limiting effect of ischemic preconditioning through augmentation of 5'-nucleotidase activity.

Authors:  M Kitakaze; M Hori; T Morioka; T Minamino; S Takashima; H Sato; Y Shinozaki; M Chujo; H Mori; M Inoue
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

Review 4.  Neuronal control of coronary blood flow.

Authors:  D Baumgart; G Heusch
Journal:  Basic Res Cardiol       Date:  1995 Mar-Apr       Impact factor: 17.165

5.  Alpha 1-adrenergic blockade reduces exercise-induced regional myocardial ischemia in dogs.

Authors:  B D Guth; T Miura; E Thaulow; G Heusch; J Ross
Journal:  Basic Res Cardiol       Date:  1993 May-Jun       Impact factor: 17.165

Review 6.  Pharmacological mechanisms to attenuate sympathetically induced myocardial ischemia.

Authors:  R Schulz; B D Guth; G Heusch
Journal:  Cardiovasc Drugs Ther       Date:  1989-03       Impact factor: 3.727

7.  The effect of electrical neurostimulation on collateral perfusion during acute coronary occlusion.

Authors:  Jessica de Vries; Rutger L Anthonio; Mike J L Dejongste; Gillian A Jessurun; Eng-Shiong Tan; Bart J G L de Smet; Ad F M van den Heuvel; Michiel J Staal; Felix Zijlstra
Journal:  BMC Cardiovasc Disord       Date:  2007-06-27       Impact factor: 2.298

Review 8.  Pathophysiology of coronary collaterals.

Authors:  Michael Stoller; Christian Seiler
Journal:  Curr Cardiol Rev       Date:  2014-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.